Management of clinically localized prostate cancer by radical prostatectomy followed by watchful waiting

Nature Clinical Practice Urology

Volumn 2, Issue 6, 2005, Pages 298-303

  Kirby, Roger ^a,b  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

Clinically localized prostate cancer; Pathologically locally advanced prostate cancer; PSA recurrence; Salvage radiotherapy; Second line hormonal therapy

Indexed keywords

PROSTAGLANDIN E1; PROSTATE SPECIFIC ANTIGEN; SILDENAFIL;

AGED; ARTICLE; BEAM THERAPY; BONE SCINTISCANNING; CANCER HORMONE THERAPY; CANCER SCREENING; CANCER STAGING; CASE REPORT; DIGITAL RECTAL EXAMINATION; ERECTILE DYSFUNCTION; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SEMINAL VESICLE; SURGICAL APPROACH;

AGED; COMBINED MODALITY THERAPY; HUMANS; MALE; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 21344470453     PISSN: 17434270     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncpuro0210     Document Type: Article

References (18)

1. Bill-Axelson A et al. (2005) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 352: 1977-1984
2. Jani AB and Hellman S (2003) Early prostate cancer: clinical decision-making. Lancet 361: 1045-1053
3. Potosky AL et al. (2004) Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst 96: 1358-1367
4. Steineck G et al. (2002) Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 347: 790-796
5. Hull GW et al. (2002) Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 167: 528-534
6. Blute ML et al. (2001) Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 165: 119-125
7. Bolla M et al. (2004) Does post-operative radiotherapy (P-RXT) after radical prostatectomy (Px) improve progression-free survival (PFS) in pT3NO prostate cancer (PC)? (EORTC 22911) [abstract]. Proc Am Soc Clin Oncol 23: a382
8. Wirth MP et al. (2004) Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 172: 1865-1870
9. Wirth MP et al. (2004) Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. Eur Urol 45: 267-270
10. Prayer-Galetti T et al. (2000) Disease free survival in patients with pathological "C STAGE" prostate cancer at radical retropubic prostatectomy submitted to adjuvant hormonal treatment [abstract]. Eur Urol 38: a504
11. Messing EM et al. (1999) Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341: 1781-1788
12. Stephenson AJ et al. (2004) Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291: 1325-1332
13. Tiguert R et al. (2003) Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level. J Urol 170: 447-450
14. Eulau SM et al. (1998) Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer. Int J Radiat Oncol Biol Phys 41: 735-740
15. The Medical Research Council Prostate Cancer Working Party Investigators Group (1997) Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br J Urol 79: 235-246
16. Pilepich MV et al. (2005) Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of Phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61: 1285-1290
17. Bolla M et al. (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360: 103-106
18. Akaza H et al. (2004) Superior anti-tumor efficacy of bicalutamide 80 mg in combination with a luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist monotherapy as first-line treatment for advanced prostate cancer: interim results of a randomized study in Japanese patients. Jpn J Clin Oncol 34: 20-28